IP Library Granted Patent US 7,354,924
Granted Patent B2
US 7,354,924 · App. 10/969,675 · Granted Apr 8, 2008

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,354,924
App. No.
10/969,675
Granted
Apr 8, 2008
Kind
B2
Abstract

This invention provides Compounds I having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. Compound I is wherein: Q is selected from the group consisting of: m is 1 or 2; —W— is A is selected from the group consisting of C 1-6 alkoxy, aryl and heteroaryl; in which said aryl is phenyl or napthyl; said heteroaryl is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, triazinyl, furanyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothienyl, benzoimidazolyl and benzothiazolyl; and said aryl or heteroaryl is optionally substituted with one or two of the same or different members selected from the group consisting of amino, nitro, cyano, hydroxy, C 1-6 alkoxy, —C(O)NH 2 ; and C 1-6 alkyl, —NHC(O)CH 3 , halogen and trifluoromethyl.

Claims (6)

1. A compound, including pharmaceutically acceptable salts thereof,

2. A compound, including pharmaceutically acceptable salts thereof,

3. A pharmaceutical formulation which comprises an antiviral effective amount of a compound of claim 1 , and a pharmaceutically acceptable carrier.

4. A pharmaceutical formulation which comprises an antiviral effective amount of a compound of claim 2 , and a pharmaceutically acceptable carrier.

5. A method for treating mammals infected with the HIV virus, comprising administering to said mammal an antiviral effective amount of a compound of claim 1 .

6. A method for treating mammals infected with the HIV virus, comprising administering to said mammal an antiviral effective amount of a compound of claim 2 .

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 039324 FRAME: 0016. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 8, 2016
From: BRISTOL-MYERS SQUIBB COMPANY
To: VIIV HEALTHCARE UK (NO. 4) LIMITED
Reel/Frame 039945/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2016
From: BRISTOL-MYERS SQUIBB COMPANY
To: VIIV HEALTHCARE (NO. 4) LIMITED
Reel/Frame 039324/0016 →